Loading...
•
Dec 31, 2025
CareDx Q4 2025 Earnings Report
CareDx reported its fourth quarter 2025 financial results, showing strong revenue growth driven by testing services and digital solutions.
Key Takeaways
CareDx achieved a 25% year-over-year revenue increase in Q4 2025, reaching $108.4 million. While the company reported a GAAP net loss of $4.1 million, it maintained positive adjusted EBITDA and strong cash flow from operations, ending the year with a solid cash position of approximately $200 million.
Total revenue for Q4 2025 grew 25% year-over-year to $108.4 million.
Testing services volume increased by 17% year-over-year to approximately 53,000 tests.
Patient and digital solutions revenue saw significant growth of 47% compared to the prior year.
The company ended 2025 with $201 million in cash, equivalents, and marketable securities after $88 million in share repurchases.
Revenue by Segment
Forward Guidance
For the full year 2026, CareDx expects revenue to be in the range of $420 million to $444 million and adjusted EBITDA between $30 million and $45 million.
Positive Outlook
- Expected annual revenue growth of 11% to 17% over 2025.
- Anticipated positive adjusted EBITDA for the full year 2026.
- Continued momentum in core testing services and digital solutions.
- Expansion into cell therapy and hematologic malignancies with AlloHeme.
- Advanced Epic Aura integrations improving workflow across transplant programs.
Challenges Ahead
- Estimated 6-month impact of Medicare LCD of approximately $7.5 million.
- GAAP net loss reported for the full year 2025.
- Decrease in adjusted EBITDA compared to the prior year quarter.
- Uncertainty regarding global economic and marketplace factors.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...